Abstract
AbstractActivatable phototheranostics holds promise for precision cancer treatment owing to the “turn‐on” signals and therapeutic effects. However, most activatable phototheranostic probes only possess photodynamic therapy (PDT) or photothermal therapy (PTT), which suffer from poor therapeutic efficacy due to deficient cellular oxygen and complex tumor microenvironment. We herein report a dual‐locked activatable phototheranostic probe that activates near‐infrared fluorescence (NIRF) signals in tumor, triggers PDT in response to a tumor‐periphery biomarker, and switches from PDT to PTT upon detecting a tumor‐core‐hypoxia biomarker. This PDT‐PTT auto‐regulated probe exhibits complete tumor ablation under the photoirradiation of a single laser source by producing cytotoxic singlet oxygen at the tumor periphery and generating hyperthermia at tumor‐core where is too hypoxic for PDT. This dual‐locked probe represents a promising molecular design approach toward precise cancer phototheranostics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
